Personnel Information

写真a

NAGANO Yoshiko


Job title

Assistant Professor

Campus Career 【 display / non-display

  • 2013.07
    -
    2018.03
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Bio-Environmental Response, Immunotherapeutics, Assistant Professor
  • 2018.04
    -
    Now
    Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Medical and Dental Sciences, Bio-Environmental Response, Immunotherapeutics, Assistant Professor

Research Areas 【 display / non-display

  • Tumor biology

  • Molecular biology

  • Immunology

 

Published Papers & Misc 【 display / non-display

  • Kannagi M, Hasegawa A, Nagano Y, Kimpara S, Suehiro Y. Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL. Retrovirology. 2019.08; 16 (1): 23.

  • Kannagi M, Hasegawa A, Nagano Y, Iino T, Okamura J, Suehiro Y. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy. Cancer Science. 2019.03; 110 (3): 849-857.

  • Sawada L, Nagano Y, Hasegawa A, Kanai H, Nogami K, Ito S, Sato T, Yamano Y, Tanaka Y, Masuda T, Kannagi M.. IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog.. 2017.09; 13 (9): e1006597.

  • Sato M, Kadota M, Tang B, Yang HH, Yang YA, Shan M, Weng J, Welsh MA, Flanders KC, Nagano Y, Michalowski AM, Clifford RJ, Lee MP, Wakefield LM. An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer Breast Cancer Research. 2014.06; 16 (3): R57.

Conference Activities & Talks 【 display / non-display

  • 米田 建、永野 佳子、長谷川 温彦、近藤 伸世、石澤 未来、松岡 将太郎、増田 貴夫、神奈木 真理. 免疫調節薬レナリドミドはHTLV-1感染細胞のサイトカイン産生に影響し増殖を抑制する. 第67回日本ウイルス学会学術集会 2019.10.30

  • Mari Kannagi, Yoshiko Nagano, Takeru Yoneda, Jian-Chun Zhang, Takao Masuda, Atsuhiko Hasegawa. Lenalidomide inhibits proliferation of HTLV-1-infected cells through suppression of IRF4 and IL-10. 2019.09.28

  • Yoshiko Nagano, Jianchun Zhang, Atsuhiko Hasegawa, Takao Masuda, Mari Kannagi. Growth inhibition of HTLV-1-infected cells by regulation of IRF4 is accompanied by increased SOCS3 expression. 第78回日本癌学会学術集会 2019.09.26

  • JIANCHUN ZHANG、永野 佳子、長谷川 温彦、片桐 邦子、倉橋 初実、増田 貴夫、神奈木 真理. IRF4制御によるHTLV-1感染細胞の増殖低下はSOCS3発現の増大を伴う. 第6回日本HTLV-1学会学術集会 2019.08.24

  • Hasegawa A, Iino T, Shiratsuchi M, Utsunomiya H, Ohno H, Kitaura K, Matsutani T, Suxuki R, Nagano Y, Matsuoka M, Kannagi M, Suehiro Y. Clonal analysis of residual ATL cells and anti-HTLV-1 Tax CTL following a dendritic cell-based anti-ATL immunotherapy targeting Tax. 2019.04.24 Peru

display all >>